An integrated presentation of the basic science and clinical applications of anticancer agents Aimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of ...
Author: Adam Todd
Publisher: John Wiley & Sons
An integrated presentation of the basic science and clinical applications of anticancer agents Aimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications. After heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year. Anticancer Therapeutics is divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents — their discovery, synthesis, mode of action, mechanisms of resistance, and adverse reactions. Section 3 focuses on specific cancers, explaining how and why the various agents discussed in Section 2 are used, both individually and in combination, to treat different cancers. Integrates aspects of basic science, including chemistry and pharmacology and clinical medicine in relation to cancer therapeutics Written by an author team comprising specialists in medicinal chemistry, pharmacology, and oncology Features full-color images throughout illustrating how drugs bind to cellular targets and exert their pharmacological effect Divided into three sections, covering the etiology and cellular and molecular basis of cancer, anticancer agents, and drug applications for different cancers. Providing the reader with an integrated understanding of all aspects of the science of anticancer agents, this is an ideal textbook for undergraduates studying medicine, nursing, medicinal chemistry, pharmacy, pharmacology and other allied heath / life sciences. It is also a valuable bench reference for pharmacists, medics, and pharmaceutical researchers working in both academia and industry.
This is also true for cancer, despite the aura of sanctity often of surrounding this dreaded disease and the apparent willingness the general population to spend large sums in this area and do "everything possible" for the patients.
Author: Niels Neymark
Publisher: Springer Science & Business Media
With ever increasing demands on the constrained resources available for health care services, no one involved in decision making in health care can continue to ignore the economic costs of the services provided or the relative value for money offered by the available treatments. Economic evaluation has therefore become an important and indispensable tool for medical deci sion making, alongside the well-known methods for clinical eval uation. This is also true for cancer, despite the aura of sanctity often of surrounding this dreaded disease and the apparent willingness the general population to spend large sums in this area and do "everything possible" for the patients. In recent years, articles dealing with assessing the costs and benefits of various cancer treatments have begun to appear in scientific medical and eco nomic journals. This book provides a comprehensive survey and assessment of the current state of the art of economic evaluations and cost ana lyses in cancer. It gives an introduction to the methods available for economic evaluations, before surveying and assessing the available publications. Separate chapters are devoted to the most prevalent cancers, and in each chapter the current clinical prac tice and research problems are summarized in order to provide a background for the economic analyses. At the end, a summary assessment of the literature is provided along with some sugges tions for a future research agenda.
This book focuses on the analysis of cancer dynamics and the mathematically based synthesis of anticancer therapy.
Author: Andrzej Świerniak
This book focuses on the analysis of cancer dynamics and the mathematically based synthesis of anticancer therapy. It summarizes the current state-of-the-art in this field and clarifies common misconceptions about mathematical modeling in cancer. Additionally, it encourages closer cooperation between engineers, physicians and mathematicians by showing the clear benefits of this without stating unrealistic goals. Development of therapy protocols is realized from an engineering point of view, such as the search for a solution to a specific control-optimization problem. Since in the case of cancer patients, consecutive measurements providing information about the current state of the disease are not available, the control laws are derived for an open loop structure. Different forms of therapy are incorporated into the models, from chemotherapy and antiangiogenic therapy to immunotherapy and gene therapy, but the class of models introduced is broad enough to incorporate other forms of therapy as well. The book begins with an analysis of cell cycle control, moving on to control effects on cell population and structured models and finally the signaling pathways involved in carcinogenesis and their influence on therapy outcome. It also discusses the incorporation of intracellular processes using signaling pathway models, since the successful treatment of cancer based on analysis of intracellular processes, might soon be a reality. It brings together various aspects of modeling anticancer therapies, which until now have been distributed over a wide range of literature. Written for researchers and graduate students interested in the use of mathematical and engineering tools in biomedicine with special emphasis on applications in cancer diagnosis and treatment, this self-contained book can be easily understood with only a minimal basic knowledge of control and system engineering methods as well as the biology of cancer. Its interdisciplinary character and the authors’ extensive experience in cooperating with clinicians and biologists make it interesting reading for researchers from control and system engineering looking for applications of their knowledge. Systems and molecular biologists as well as clinicians will also find new inspiration for their research.
This book aims to emphasize skin toxicity associated with EGFR-, VEGF- and BRAF- inhibitors, focusing particularly on their clinical presentation, histopathological findings, and specific therapeutic options.
Author: Anna Campanati
Targeted cancer therapies have revolutionized the therapeutic management of many neoplasms, modifying patients' prognosis and overall survival. These drugs block the cancer's growth and spread by interfering with specific molecules which play a crucial role in the proliferation, differentiation and survival of cancer cells. Targeted therapies act selectively on specific molecular targets related to cancers, whereas most of the conventional chemotherapies act on all rapidly dividing normal and neoplastic cells. Moreover, targeted therapies are often cytostatic and non-cytotoxic as standard chemotherapies. Taken together, these aspects appear important in reducing systemic toxicity and ensuring an improved safety profile. The inhibition of epidermal growth factor receptor (EGFR), vascular growth factor (VEGF) and BRAF represents major achievements in research and development of solid tumors' epithelial therapy. This class of biologics is currently widely used in the treatment of metastatic and unresponsive neoplasms of the colon, pancreas, lung, (NSCLC), breast, head and neck and melanoma. This book aims to emphasize skin toxicity associated with EGFR-, VEGF- and BRAF- inhibitors, focusing particularly on their clinical presentation, histopathological findings, and specific therapeutic options.
The book is unique in providing molecular structures for all anticancer agents, discussing them in terms of history of development, chemistry, mechanism of action, structure–function relationships, and pharmacology.
Author: David E. Thurston
Publisher: CRC Press
While drug therapies developed in the last 80 years have markedly improved treatment outcomes and the management of some types of cancers, the lack of effectiveness and side effects associated with the most common treatment types remain unacceptable. However, recent technological advances are leading to improved therapies based on targeting distinct biological pathways in cancer cells. Chemistry and Pharmacology of Anticancer Drugs is a comprehensive survey of all families of anticancer agents and therapeutic approaches currently in use or in advanced stages of clinical trials, including biological-based therapies. The book is unique in providing molecular structures for all anticancer agents, discussing them in terms of history of development, chemistry, mechanism of action, structure–function relationships, and pharmacology. It also provides relevant information on side effects, dosing, and formulation. The authors, renowned scientists in cancer research and drug discovery, also provide up-to-date information on the drug discovery process, including discussions of new research tools, tumor-targeting strategies, and fundamental concepts in the relatively new areas of precision medicine and chemoprevention. Chemistry and Pharmacology of Anticancer Drugs is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists involved in the development of new anticancer therapies. Its breadth of coverage, clear explanations, and illustrations also make it suitable for undergraduate and postgraduate courses in medicine, pharmacy, nursing, dentistry, nutrition, the biomedical sciences, and related disciplines. Key Features: Summarizes the fundamental causes of cancer, modes of treatment, and strategies for cancer drug discovery Brings together a broad spectrum of information relating to the chemistry and pharmacology of all families of anticancer agents and therapies Includes up-to-date information on cutting-edge aspects of cancer treatments such as biomarkers, pharmacogenetics, and pharmacogenomics Features new chapters on the "Evolution of Anticancer Therapies", "Antibody-Based Therapies", and "Cancer Chemoprevention"
Unconventional therapy has been implemented to decrease the adverseness of treatment. The third chapter, also by Muhammad Imran Qadir, elaborates on the risk factors of breast cancer, such as early menarche and late menopause.
Author: George Moyer
In the first chapter, I-Ling Hung, Yu-Chiang Hung, and Wen-Long Hu examine the synergistic processes of herbal ingredients in order to help researchers discover new phytomedicines. Next, in the second chapter, Muhammad Imran Qadir gives a synopsis of the discussion regarding the cure of developed prostate cancer by using androgen deprivation therapy. Ddiethylstilbestrol was previously used to achieve androgen deprivation, but luteinising hormone-releasing hormone (LHRH) replaced it and a slew of detrimental effects ensued. Unconventional therapy has been implemented to decrease the adverseness of treatment. The third chapter, also by Muhammad Imran Qadir, elaborates on the risk factors of breast cancer, such as early menarche and late menopause. In the fourth chapter, he discusses the impact of synthetic peptides in liver cancer management. Continuing, he uses the fifth chapter to discuss the use of a hepatic sgRNA or single guide RNA delivery system to target a large proportion of gene sets to induce the hepatocellular carcinoma (HCC) and intra-hepatic cholangio-carcinoma (ICC), concluding that the CRISPR/Cas9 gene targeting could be used to manage HCC, the predominant cause of cancer-related deaths. In the sixth chapter written by Muhammad Imran Qadir, the decrease in potential risk of cancer via blockers of IGF-1R in prostate and colon carcinomas and use of anti-IGF therapy in grouping of cytotoxic drugs is examined. In the seventh chapter, Sara Tabassum joins Muhammad Imran Qadir in exploring the potential for telomere, or its enzyme, to be used as a target drug or in the screening process for treatment of cancer. Muhammad Imran Qadir goes on to examine how CK-19 helps to differentiate papillary thyroid carcinomas from other malignant and benign forms in the eighth chapter. In the ninth chapter, he analyses the distinctive biological properties of Nanoparticles due to small size and a large surface area to volume ratio. In the tenth chapter, Muhammad Imran Qadir studies the part BRCA mutations play in breast cancer development. Simona Martinetti, Mauro Partrone, Giorgio Calabrese, and Elia Ranzato review current research that suggests potential uses of ascorbate in cancer treatment in the eleventh chapter. Lastly, the twelfth chapter provided by Muhammad Imran Qadir presents a study that offers a new modernisation for Caspase substrates.
These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for present and future developments in the field.
Author: Beverly A. Teicher
Publisher: Humana Press
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Written by the winner of the 2008 Mike Price Fellowship "This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject.
Author: Sotiris Missailidis
Publisher: John Wiley & Sons
Written by the winner of the 2008 Mike Price Fellowship "This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject." Anticancer Research, November - December 2008 This book provides a clear introduction to the area, with an overview of the various drug design and development approaches for cancer therapeutics and their progress in today’s multidisciplinary approach to cancer treatment. Clearly structured throughout, the book not only provides information on currently used molecular treatment approaches, but also describes the various agents that are currently at various stages of development and clinical trials, thus making them the drugs of tomorrow. The book goes on to present current therapeutic regimes including their indications and side effects, as well as their position in the international market in terms of sales and development costs. Furthermore, coverage of our advancement in the understanding of cancer biology and how this has driven the drug discovery process is clearly discussed. Modern drug discovery aspects, through genomic, proteomic and metabolomic approaches are referred to as well as combinatorial chemistry techniques and discovery of chemotherapeutic agents from plant extracts, re-use of old drugs and drugs from other indications, or de novo rational drug design. Including contributions from leading experts in the field, this book provides the reader with a complete overview of the various types of therapeutic agents, current and emerging, as well as other aspects associated with anticancer therapy, drug design, resistance and clinical trials in oncology.